{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T20:48:34Z","timestamp":1790196514509,"version":"4.1.0"},"reference-count":20,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T00:00:00Z","timestamp":1769558400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T00:00:00Z","timestamp":1769558400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Liver International"],"published-print":{"date-parts":[[2026,3]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:p>Intrahepatic cholestasis of pregnancy (ICP) presents with cholestatic pruritus, elevated sBA and increased risk of adverse perinatal outcomes. Volixibat is a minimally absorbed IBAT inhibitor that interrupts enterohepatic recirculation. We describe four patients with ICP with pruritus and sBA &gt; ULN treated with volixibat (20 or 80\u2009mg BID orally until delivery), with dose modifications permitted for tolerability. Daily pruritus scores, sBA, liver enzymes, perinatal outcomes and TEAEs were assessed. Over 1000 patients were invited to participate; 26 were screened, and four received volixibat. Three patients experienced reductions in pruritus from baseline regardless of volixibat dose, with intermittent relief coinciding with resumption of dosing when doses were interrupted. sBA nadir values all reached &lt;\u20096\u2009\u03bcmol\/L following volixibat. No clinically meaningful changes in laboratory parameters were observed. All patients had healthy live births. Most frequent TEAEs were gastrointestinal. Volixibat demonstrated improvements in pruritus and sBA in patients with ICP.<\/jats:p>\n                  <jats:p>\n                    <jats:bold>Trial Registration:<\/jats:bold>\n                    NCT04718961\n                  <\/jats:p>","DOI":"10.1111\/liv.70523","type":"journal-article","created":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T13:23:35Z","timestamp":1769606615000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Efficacy, Safety and Tolerability of Volixibat, an\n                    <scp>IBAT<\/scp>\n                    Inhibitor, in Patients With Intrahepatic Cholestasis of Pregnancy"],"prefix":"10.1111","volume":"46","author":[{"given":"Caroline","family":"Ovadia","sequence":"first","affiliation":[{"name":"Department of Women and Children's Health King's College London  London UK"},{"name":"Centre for Reproductive Health, Institute for Regeneration and Repair University of Edinburgh  Edinburgh UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophia","family":"Stone","sequence":"additional","affiliation":[{"name":"St Richard's Hospital University Hospitals Sussex NHS Foundation Trust  Chichester UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Baha","family":"Sibai","sequence":"additional","affiliation":[{"name":"Division of Maternal\u2010Fetal Medicine, Department of Obstetrics, Gynecology and Reproductive Sciences, McGovern Medical School, Texas Medical Center The University of Texas  Houston Texas USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tiago","family":"Nunes","sequence":"additional","affiliation":[{"name":"Mirum Pharmaceuticals, Inc.  Foster City California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Douglas B.","family":"Mogul","sequence":"additional","affiliation":[{"name":"Mirum Pharmaceuticals, Inc.  Foster City California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jayshree","family":"Krishnaswami","sequence":"additional","affiliation":[{"name":"Mirum Pharmaceuticals, Inc.  Foster City California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Kahng","sequence":"additional","affiliation":[{"name":"Mirum Pharmaceuticals, Inc.  Foster City California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Furong","family":"Li","sequence":"additional","affiliation":[{"name":"Mirum Pharmaceuticals, Inc.  Foster City California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qurratul Ann","family":"Warsi","sequence":"additional","affiliation":[{"name":"Mirum Pharmaceuticals, Inc.  Foster City California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elaine","family":"Chien","sequence":"additional","affiliation":[{"name":"Mirum Pharmaceuticals, Inc.  Foster City California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pamela","family":"Vig","sequence":"additional","affiliation":[{"name":"Mirum Pharmaceuticals, Inc.  Foster City California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"Williamson","sequence":"additional","affiliation":[{"name":"Department of Women and Children's Health King's College London  London UK"},{"name":"Institute of Reproductive and Developmental Biology Imperial College London  London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,1,28]]},"reference":[{"key":"e_1_2_12_2_1","doi-asserted-by":"publisher","DOI":"10.1080\/13557859998173"},{"key":"e_1_2_12_3_1","unstructured":"C.OvadiaandC.Williamson \u201cIntrahepatic Cholestasis of Pregnancy \u201dBMJ Best Practice reviewed January 20 2025 https:\/\/bestpractice.bmj.com\/topics\/en\u2010us\/800."},{"key":"e_1_2_12_4_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.26617"},{"key":"e_1_2_12_5_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.20336"},{"key":"e_1_2_12_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)31877-4"},{"key":"e_1_2_12_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)31270-X"},{"key":"e_1_2_12_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2468-1253(21)00074-1"},{"key":"e_1_2_12_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)01256-3"},{"key":"e_1_2_12_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2468-1253(24)00080-3"},{"key":"e_1_2_12_11_1","doi-asserted-by":"publisher","DOI":"10.1097\/HC9.0000000000000153"},{"key":"e_1_2_12_12_1","unstructured":"K. V.Kowdley M. L.Shiffman D.Weinstein et\u00a0al. \u201cVolixibat for Cholestatic Pruritus in Primary Biliary Cholangitis: An Adaptive Randomized Placebo\u2010Controlled Phase 2b Trial (VANTAGE): Interim Results \u201dPresented the American Association for the Study of Liver Diseases (AASLD) The Liver Meeting; San Diego CA USA (2024) https:\/\/www.natap.org\/2024\/AASLD\/AASLD_85.htm."},{"key":"e_1_2_12_13_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-29931-z"},{"key":"e_1_2_12_14_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-020-2434-2"},{"key":"e_1_2_12_15_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-018-25214-0"},{"key":"e_1_2_12_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2022.10.032"},{"key":"e_1_2_12_17_1","doi-asserted-by":"publisher","DOI":"10.1136\/gut.2008.159541"},{"key":"e_1_2_12_18_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-017-11626-x"},{"key":"e_1_2_12_19_1","doi-asserted-by":"publisher","DOI":"10.1186\/s40360-018-0200-y"},{"key":"e_1_2_12_20_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13318-017-0429-7"},{"key":"e_1_2_12_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2025.05.018"}],"container-title":["Liver International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/liv.70523","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/liv.70523","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/liv.70523","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,23]],"date-time":"2026-03-23T13:55:53Z","timestamp":1774274153000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/liv.70523"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,28]]},"references-count":20,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["10.1111\/liv.70523"],"URL":"https:\/\/doi.org\/10.1111\/liv.70523","archive":["Portico"],"relation":{},"ISSN":["1478-3223","1478-3231"],"issn-type":[{"value":"1478-3223","type":"print"},{"value":"1478-3231","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,28]]},"assertion":[{"value":"2025-05-30","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-01-10","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-01-28","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e70523"}}